US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mineralys Therapeutics, Inc.

14.23

+0.29002.08%

Volume:699.27K

Turnover:9.93M

Market Cap:923.19M

PE:-3.88

High:14.48

Open:13.95

Low:13.73

Close:13.94

Loading ...

Overview Company News Filings

Promising Potential of Lorundrostat Drives Buy Rating for Mineralys Therapeutics, Inc.

Mineralys' drug for persistent hypertension succeeds in two trials

Mineralys Therapeutics Up Over 55%, on Pace for Record Percent Increase -- Data Talk

Goldman Sachs Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics Shares Hit 52-Week High on Hypertension Study Results

Mineralys Therapeutics Shares up 31% After Co's Blood Pressure Drug Meets Goal in Trials

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Primo Brands, Cracker Barrel, Redfin

Mineralys Therapeutics Says Lorundrostat Met Trial Endpoints for Treating Hypertension; Shares Up Pre-Bell

MT Newswires Live

Mineralys Therapeutics Shares Resume Trading, Jump 40% Premarket After Co's Blood Pressure Drug Meets Goal in Trials

THOMSON REUTERS

CORRECTED-UPDATE 2-Mineralys' blood pressure drug meets goal in trials, shares soar

Mineralys Posts Positive Lorundrostat Study Results for Uncontrolled Hypertension

Mineralys Therapeutics' blood pressure drug meets goal in trials

BRIEF-Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension

Mineralys Therapeutics Announces Positive Topline Results From Launch-Htn and Advance-Htn Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

THOMSON REUTERS

Mineralys Therapeutics Inc: Launch-Htn Met Its Primary Endpoint

THOMSON REUTERS

Mineralys Therapeutics Inc: Lorundrostat Demonstrated a Favorable Safety and Tolerability Profile in Both Pivotal Trials

THOMSON REUTERS

Mineralys Therapeutics Shares Halted for News Pending Premarket

THOMSON REUTERS

Stocks to Watch: Cognizant Technology Solutions, Mineralys Therapeutics, PDF Solutions

Mineralys Therapeutics Rises Ahead of Hypertension-Drug Trial Data

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MLYS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MLYS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MLYS\",,,,,undefined,":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":14.23,"timestamp":1746041892345,"preClose":13.94,"halted":0,"volume":699267,"delay":0,"floatShares":43055858,"shares":64876228,"eps":-3.663179,"marketStatus":"Trading","change":0.29,"latestTime":"04-30 15:38:13 EDT","open":13.95,"high":14.48,"low":13.725,"amount":9929776.006488001,"amplitude":0.054161,"askPrice":14.24,"askSize":200,"bidPrice":14.22,"bidSize":513,"shortable":3,"etf":0,"ttmEps":-3.663179,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":13.94,"preHourTrading":{"tag":"盘前","latestPrice":14,"preClose":13.94,"latestTime":"09:29 EDT","volume":1404,"amount":19539.729143999997,"timestamp":1746019755017},"postHourTrading":{"tag":"盘后","latestPrice":13.94,"preClose":13.94,"latestTime":"16:05 EDT","volume":11669,"amount":162665.86,"timestamp":1745957110457},"volumeRatio":1.319845,"impliedVol":0.4389,"impliedVolPercentile":0.34},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MLYS\",,,,,undefined,":{"symbol":"MLYS","floatShares":43055858,"roa":"-52.56%","roe":"-82.24%","lyrEps":-3.663179,"volumeRatio":1.319845,"shares":64876228,"dividePrice":0,"high":14.48,"amplitude":0.054161,"preClose":13.94,"low":13.725,"week52Low":8.241,"pbRate":"4.83","week52High":18.38,"institutionHeld":0,"latestPrice":14.23,"committee":0.43899,"eps":-3.663179,"divideRate":0,"volume":699267,"delay":0,"ttmEps":-3.663179,"open":13.95,"prevYearClose":12.31,"prevWeekClose":13.34,"prevMonthClose":15.88,"prevQuarterClose":15.88,"fiveDayClose":13.53,"twentyDayClose":13.84,"sixtyDayClose":9.93},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MLYS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518008279","title":"Promising Potential of Lorundrostat Drives Buy Rating for Mineralys Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2518008279","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518008279?lang=en_us&edition=fundamental","pubTime":"2025-03-10 23:05","pubTimestamp":1741619112,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on MLYS stock, giving a Buy rating on March 7. Matthew Caufield has gi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-potential-of-lorundrostat-drives-buy-rating-for-mineralys-therapeutics-inc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-potential-of-lorundrostat-drives-buy-rating-for-mineralys-therapeutics-inc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLYS"],"gpt_icon":0},{"id":"2518276406","title":"Mineralys' drug for persistent hypertension succeeds in two trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2518276406","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518276406?lang=en_us&edition=fundamental","pubTime":"2025-03-10 23:02","pubTimestamp":1741618944,"startTime":"0","endTime":"0","summary":"UPDATE 3-Mineralys' drug for persistent hypertension succeeds in two trialsUpdates share move, add details throughout, adds analyst's comments in paragraphs 6 and 7, company comments from conference c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT0WQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0949170426.SGD","LU0211326839.USD","LU2089283258.USD","LU0211327993.USD","LU1496350502.SGD","LU0557290698.USD","LU1481600234.SGD","LU2091194634.USD","LU1880407132.USD","LU0310800965.SGD","LU1064927863.SGD","LU0969580561.USD","LU1323610961.USD","LU1267930490.SGD","LU1814569148.SGD","LU0882574055.USD","LU1023059063.AUD","LU0266013472.USD","LU0114720955.EUR","LU0496365809.HKD","SG9999001176.SGD","LU0128525689.USD","03165","LU0997586432.USD","IE00BFTCPJ56.SGD","LU0976567544.SGD","LU0211328371.USD","LU2279689827.SGD","LU0158827948.USD","AZN.UK","LU0047473722.SGD","LU2023251221.USD","LU2324357040.USD","LU1057294990.SGD","LU1267930813.SGD","LU0738911758.USD","LU0128525929.USD","LU0310799852.SGD","LU1983299246.USD","LU1003076772.USD","MLYS","LU0823416689.USD","LU1880407215.USD","LU1153584641.USD","SG9999013999.USD","LU1267930573.SGD","IE0009355771.USD","LU0553294199.USD","IE00BJT1NW94.SGD","LU0640478417.SGD"],"gpt_icon":0},{"id":"2518220739","title":"Mineralys Therapeutics Up Over 55%, on Pace for Record Percent Increase -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220739","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518220739?lang=en_us&edition=fundamental","pubTime":"2025-03-10 22:19","pubTimestamp":1741616340,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc.  is currently at $16.32, up $5.81 or 55.18%. --Would be highest close since June 30, 2023, when it closed at $17.05. --Down 14.71% from its all-time closing high of $19.14 on March 3, 2023. --Up 23.11% from 52 weeks ago , when it closed at $13.26. --Up 86.36% from its 52-week closing low of $8.76 on Feb. 25, 2025. --Traded as high as $16.55; highest intraday level since Feb. 27, 2024, when it hit $16.90. --Up 57.32% at today's intraday high; largest intraday percent increase on record ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","MLYS"],"gpt_icon":0},{"id":"2518271852","title":"Goldman Sachs Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518271852?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:57","pubTimestamp":1741615031,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Richard Law CFA maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report) on March 7 and set a price t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-remains-a-buy-on-mineralys-therapeutics-inc-mlys?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-remains-a-buy-on-mineralys-therapeutics-inc-mlys?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4552","LU2750360641.GBP","IE00BSNM7G36.USD","IE0034235188.USD","BK4516","IE0004086264.USD","LU0096364046.USD","BK4504","LU1868837300.USD","LU0061475181.USD","LU1868837136.USD","BK4139","IE0004091025.USD","LU2471134879.HKD","LU1791807156.HKD","LU2237443622.USD","LU2750360997.AUD","LU2471134523.USD","IE0002270589.USD","BK4585","LU1868836757.USD","CFA","IE00B19Z3581.USD","LU2237443465.HKD","LU2237443549.SGD","BK4588","IE00B19Z3B42.SGD","LU2237438978.USD","LU2471134952.CNY","MLYS","BK4127","LU2237443895.HKD","LU1668664300.SGD","LU0106831901.USD","LU2237443382.USD","IE00BFXG1179.USD","LU1868836591.USD","BK4550","LU2237443978.SGD","BK4533","LU1868836914.USD","LU2471134796.USD"],"gpt_icon":0},{"id":"2518837227","title":"Mineralys Therapeutics Shares Hit 52-Week High on Hypertension Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518837227","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518837227?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:57","pubTimestamp":1741615020,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics shares surged to a new 52-week high Monday after the clinical-stage biopharmaceutical company reported positive study results for its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.Shares of the Radnor, Pa., company were recently changing hands at $15.07, up 43%, after touching a 52-week high of $15.64 early in the session.Mineralys said a pair of pivotal studies of lorundrostat achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints, and that the results demonstrate the opportunity for the drug in third-line or later treatment.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS","LENZ"],"gpt_icon":0},{"id":"2518224903","title":"Mineralys Therapeutics Shares up 31% After Co's Blood Pressure Drug Meets Goal in Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518224903?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:34","pubTimestamp":1741613649,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT10V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2518221618","title":"BUZZ-U.S. STOCKS ON THE MOVE-Primo Brands, Cracker Barrel, Redfin","url":"https://stock-news.laohu8.com/highlight/detail?id=2518221618","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518221618?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:13","pubTimestamp":1741612386,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Primo Brands, Cracker Barrel, RedfinEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL6N3PT0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","CBRL","WSM","LU1069347547.HKD","IE00BK4W5M84.HKD","GB00BDT5M118.USD","LU0130518102.USD","IE00BWXC8680.SGD","DASH","IE00B894F039.SGD","RDFN","BECN","CKPT","LU1057294990.SGD","LU1923622614.USD","IE0004086264.USD","TRVI","BK4209","IE00B19Z9Z06.USD","LU0128525929.USD","BK4604","DXCM","RKT","LU1670628061.USD","PRMB","EXE","IE00B2B36J28.USD","TSYW.SI","FBIO","LU1974910355.USD","BK4581","LU1868836757.USD","LU2023250330.USD","LU1868836914.USD","LU0323591593.USD","ABNB","LU2237443895.HKD","BK4229","HUT","IE0004091025.USD","LU2360106947.USD","TKO","LU0203347892.USD"],"gpt_icon":1},{"id":"2518223344","title":"Mineralys Therapeutics Says Lorundrostat Met Trial Endpoints for Treating Hypertension; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2518223344","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518223344?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:12","pubTimestamp":1741608769,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics  shares were up premarket Monday after the company said lorundrostat met primary endpoints in both the phase 3 Launch-HTN and phase 2 Advance-HTN trials in patients with uncontrolled hypertension or resistant hypertension.The company said the phase 3 study showed a statistically significant drop in systolic blood pressure compared with placebo by week six until week 12.In the phase 2 trial, lorundrostat also led to a statistically significant placebo-adjusted drop of 7.9 mmHg in systolic pressure at week 12, Mineralys said.Mineralys said the treatment was generally well tolerated in both studies, with low rates of serious side effects and elevated potassium levels. The company said it plans to present more data at a medical conference later this month and continue collecting longer-term results in an extension study.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","MLYS","BK4139"],"gpt_icon":0},{"id":"2518824714","title":"Mineralys Therapeutics Shares Resume Trading, Jump 40% Premarket After Co's Blood Pressure Drug Meets Goal in Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2518824714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518824714?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:31","pubTimestamp":1741606310,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT0UH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2518624785","title":"CORRECTED-UPDATE 2-Mineralys' blood pressure drug meets goal in trials, shares soar","url":"https://stock-news.laohu8.com/highlight/detail?id=2518624785","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518624785?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:22","pubTimestamp":1741605768,"startTime":"0","endTime":"0","summary":"CORRECTED-UPDATE 2-Mineralys' blood pressure drug meets goal in trials, shares soarCorrects paragraph 3 to say the drug showed reduction of 7.9 mmHg, not 11.7 mmHg, in mid-stage studyMarch 10  - Mineralys Therapeutics MLYS.O said on Monday its experimental  drug met the main goal of lowering blood pressure in patients with uncontrolled or resistant hypertension in late- and mid- stage trials, sending its shares up about 43% before the bell.In the late-stage study, the treatment called lorundrostat showed a placebo-adjusted reduction in systolic blood pressure by 9.1 mmHg  at week six. The benefit was sustained through week 12, with a further reduction to 11.7 mmHg.The drug also reduced systolic blood pressure by 7.9 mmHg in a mid-stage trial when compared to a placebo, the company said.Lorundrostat inhibits the production of aldosterone, a hormone that can contribute to high blood pressure.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT0SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2518242602","title":"Mineralys Posts Positive Lorundrostat Study Results for Uncontrolled Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2518242602","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518242602?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:19","pubTimestamp":1741605540,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.Mineralys said its Phase 3 Launch-HTN and Phase 2 Advance-HTN studies achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints while showing a favorable safety and tolerability profile.The Radnor, Pa., clinical-stage biopharmaceutical company said it believes the clinical profile observed for lorundrostat supports the potential regulatory approval of the drug, which it said has the potential to be a transformative new therapy for the roughly 15 million to 20 million people in the U.S. living with uncontrolled hypertension.Trading in shares of Mineralys, which closed Friday at $10.52, was halted premarket on Monday.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mineralys Posts Positive Lorundrostat Study Results for Uncontrolled Hypertension","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":1},{"id":"2518244149","title":"Mineralys Therapeutics' blood pressure drug meets goal in trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2518244149","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518244149?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:08","pubTimestamp":1741604885,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics' blood pressure drug meets goal in trialsMarch 10  - Mineralys Therapeutics MLYS.O said on Monday its blood pressure drug, lorundrostat, met the main goal in late- and mid- stage trials.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT0RU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2518410232","title":"BRIEF-Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2518410232","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518410232?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:02","pubTimestamp":1741604522,"startTime":"0","endTime":"0","summary":"BRIEF-Mineralys Therapeutics Announces Positive Topline Results From Launch-HTN And Advance-HTN Pivotal Trials Of Lorundrostat For The Treatment Of Uncontrolled Or Resistant HypertensionMarch 10 (Reut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2518424434","title":"Mineralys Therapeutics Announces Positive Topline Results From Launch-Htn and Advance-Htn Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2518424434","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518424434?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:00","pubTimestamp":1741604410,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2518329244","title":"Mineralys Therapeutics Inc: Launch-Htn Met Its Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2518329244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518329244?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:00","pubTimestamp":1741604410,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0JY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2518244375","title":"Mineralys Therapeutics Inc: Lorundrostat Demonstrated a Favorable Safety and Tolerability Profile in Both Pivotal Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2518244375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518244375?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:00","pubTimestamp":1741604410,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0JY:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2518224169","title":"Mineralys Therapeutics Shares Halted for News Pending Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518224169?lang=en_us&edition=fundamental","pubTime":"2025-03-10 18:57","pubTimestamp":1741604247,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL4N3PT0RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2517460682","title":"Stocks to Watch: Cognizant Technology Solutions, Mineralys Therapeutics, PDF Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2517460682","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517460682?lang=en_us&edition=fundamental","pubTime":"2025-03-08 07:28","pubTimestamp":1741390080,"startTime":"0","endTime":"0","summary":"Cognizant Technology Solutions said it has been constructively engaging with Mantle Ridge, an activist firm that has built up a more than $1 billion stake in the company. Mantle Ridge believes shares of the tech-services firm are undervalued and has been privately engaging with Cognizant about its progress on boosting the share price, The Wall Street Journal reported, citing people familiar with the matter. Shares rise 5.2%, to $87.54, in after-hours trading.Mineralys Therapeutics said it plans to release data from two recent trials involving lorundrostat, a drug the biopharmaceutical company is developing as a treatment for high blood pressure. Shares gain 12%, to $11.82, in postmarket trading.PDF Solutions closed a $130 million acquisition and entered into a new credit agreement. The company, which provides data solutions for the semiconductor and electronics industries, said its acquisition of SecureWise will significantly expand its manufacturing connectivity network. It also enter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTSH","LU0072462343.USD","LU0950375773.USD","LU0823417653.USD","LU1839511570.USD","LU2087621335.USD","PDFS","LU0536402901.SGD","LU1048588211.SGD","LU1267930656.SGD","LU1048596156.SGD","LU0708995666.HKD","LU2506951958.HKD","LU0231203729.USD","LENZ","LU0006061336.USD","LU0823417737.USD","LU2506952097.USD","LU2506951875.HKD","LU0821914370.USD","MLYS","LU2506952170.USD","BK4585","BK4588","BK4134","BK4147"],"gpt_icon":1},{"id":"2517462720","title":"Mineralys Therapeutics Rises Ahead of Hypertension-Drug Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2517462720","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517462720?lang=en_us&edition=fundamental","pubTime":"2025-03-08 06:52","pubTimestamp":1741387920,"startTime":"0","endTime":"0","summary":"Shares of Mineralys Therapeutics gained after the company said it plans to release data from two recent trials involving lorundrostat, a drug the company is developing as a treatment for high blood pressure.The stock was up 13%, to $11.88, in after-hours trading Friday. Shares ended the regular session roughly flat and have lost a quarter of their value in the past year.The Radnor, Pa., biopharmaceutical company said after the bell that it would host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday morning.The Launch-HTN trial evaluated lorundrostat as an add-on therapy to an existing, prescribed background treatment of two-to-five anti-hypertensive medications, while the Advance-HTN trial evaluated the drug as an add-on therapy to a standardized background treatment of two or three anti-hypertensive medications, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","MLYS","BK4139"],"gpt_icon":0},{"id":"2517440463","title":"Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2517440463","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517440463?lang=en_us&edition=fundamental","pubTime":"2025-03-08 05:01","pubTimestamp":1741381260,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., March 07, 2025  -- Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease , obstructive sleep apnea  and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday, March 10, 2025, at 8:00 a.m. ET.The Launch-HTN trial evaluated the efficacy and safety of lorundrostat, a highly selective aldosterone inhibitor, for the treatment of uncontrolled hypertension  or resistant hypertension  as an add-on therapy to an existing, prescribed background treatment of two to five antihypertensive medications.The Advance-HTN trial evaluated the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN when used as an add-on therapy to a standardized background treatment of two or three anti-hypertensive medications.A live webcast of the confer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mineralys-therapeutics-announce-topline-data-210100331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","ET","BK4590","MLYS","BK4581","BK4561","LENZ","BK4144","BK4139","AM","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":74,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MLYS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-12","symbol":"MLYS","fiscalQuarterEnding":"2024/12","expectedEps":1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1739336400000,"reportTimeType":"pre","actualEps":-0.98},{"market":"US","date":"2024-11-11","symbol":"MLYS","fiscalQuarterEnding":"2024/09","expectedEps":-0.83,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731301200000,"reportTimeType":"post","actualEps":-1.13},{"market":"US","date":"2024-08-13","symbol":"MLYS","fiscalQuarterEnding":"2024/06","expectedEps":-0.73,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-0.83},{"market":"US","date":"2024-05-09","symbol":"MLYS","fiscalQuarterEnding":"2024/03","expectedEps":-0.68,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.7},{"market":"US","date":"2024-03-21","symbol":"MLYS","fiscalQuarterEnding":"2023/12","expectedEps":-0.85,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1710993600000,"reportTimeType":"pre","actualEps":-0.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MLYS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MLYS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.375,"buy":0.625,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1741924800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MLYS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MLYS","date":"2025-04-29","current":-4.947538,"percent":0.720755,"low":-28.120261,"twenty":-17.38032,"median":-7.18498,"eighty":-4.620348,"high":-2.455206,"avg":-9.850604,"sd":6.41563,"marketCap":879721651},"quantilePoints":[{"date":"2023-02-10","current":-25.898259,"twenty":-24.067223,"median":-21.320668,"eighty":-10.744265,"marketCap":720204681},{"date":"2023-02-17","current":-26.342543,"twenty":-26.413064,"median":-26.058397,"eighty":-23.151704,"marketCap":732559788},{"date":"2023-02-24","current":-26.298468,"twenty":-26.483585,"median":-26.320505,"eighty":-25.926348,"marketCap":731334088},{"date":"2023-03-03","current":-28.120261,"twenty":-26.483585,"median":-26.122165,"eighty":-25.407434,"marketCap":781996338},{"date":"2023-03-10","current":-23.918383,"twenty":-26.483585,"median":-26.166241,"eighty":-25.1907,"marketCap":665146310},{"date":"2023-03-17","current":-21.169392,"twenty":-26.45714,"median":-26.078089,"eighty":-23.824355,"marketCap":630826722},{"date":"2023-03-24","current":-20.744359,"twenty":-26.427757,"median":-25.591493,"eighty":-21.169392,"marketCap":618161159},{"date":"2023-03-31","current":-21.471029,"twenty":-26.354297,"median":-24.873355,"eighty":-21.103581,"marketCap":639815185},{"date":"2023-04-06","current":-19.11278,"twenty":-26.342543,"median":-23.918383,"eighty":-20.744359,"marketCap":569541742},{"date":"2023-04-14","current":-18.427243,"twenty":-26.298468,"median":-22.156566,"eighty":-20.113665,"marketCap":549113416},{"date":"2023-04-21","current":-18.879698,"twenty":-26.210316,"median":-21.471029,"eighty":-19.688632,"marketCap":562596111},{"date":"2023-04-28","current":-17.933656,"twenty":-26.122165,"median":-21.24503,"eighty":-18.783722,"marketCap":534405021},{"date":"2023-05-05","current":-20.086243,"twenty":-26.092781,"median":-21.087128,"eighty":-18.674036,"marketCap":598549966},{"date":"2023-05-12","current":-21.992037,"twenty":-26.078089,"median":-21.24503,"eighty":-18.728879,"marketCap":655340714},{"date":"2023-05-19","current":-21.745244,"twenty":-26.038705,"median":-21.457318,"eighty":-18.783722,"marketCap":647986516},{"date":"2023-05-26","current":-16.559387,"twenty":-25.898259,"median":-21.176247,"eighty":-18.591772,"marketCap":576895940},{"date":"2023-06-02","current":-16.969854,"twenty":-25.407434,"median":-21.12826,"eighty":-18.572577,"marketCap":591195768},{"date":"2023-06-09","current":-17.990156,"twenty":-25.1907,"median":-20.744359,"eighty":-18.397637,"marketCap":626741057},{"date":"2023-06-16","current":-18.271619,"twenty":-24.932123,"median":-20.360458,"eighty":-18.2552,"marketCap":636546653},{"date":"2023-06-23","current":-18.869727,"twenty":-24.820464,"median":-20.099954,"eighty":-18.341985,"marketCap":657383546},{"date":"2023-06-30","current":-19.432652,"twenty":-24.438476,"median":-19.960543,"eighty":-18.318529,"marketCap":676994740},{"date":"2023-07-07","current":-18.177798,"twenty":-23.894876,"median":-19.784607,"eighty":-18.295074,"marketCap":633278121},{"date":"2023-07-14","current":-18.224708,"twenty":-23.631036,"median":-19.510392,"eighty":-18.189525,"marketCap":634912387},{"date":"2023-07-21","current":-17.403775,"twenty":-22.844845,"median":-19.344695,"eighty":-18.039908,"marketCap":606312730},{"date":"2023-07-28","current":-16.395201,"twenty":-22.373196,"median":-18.879698,"eighty":-17.903799,"marketCap":571176008},{"date":"2023-08-04","current":-15.996462,"twenty":-22.189472,"median":-18.77395,"eighty":-17.722767,"marketCap":557284746},{"date":"2023-08-11","current":-13.235538,"twenty":-22.153824,"median":-18.728996,"eighty":-17.560925,"marketCap":536039287},{"date":"2023-08-18","current":-12.28726,"twenty":-22.129144,"median":-18.70554,"eighty":-17.406121,"marketCap":497634033},{"date":"2023-08-25","current":-13.043865,"twenty":-22.057849,"median":-18.632904,"eighty":-17.159841,"marketCap":528276523},{"date":"2023-09-01","current":-12.953072,"twenty":-21.986553,"median":-18.590018,"eighty":-16.81974,"marketCap":524599424},{"date":"2023-09-08","current":-11.823209,"twenty":-21.9701,"median":-18.578061,"eighty":-16.550005,"marketCap":478839973},{"date":"2023-09-15","current":-12.055235,"twenty":-21.909773,"median":-18.516678,"eighty":-16.005844,"marketCap":488237003},{"date":"2023-09-21","current":-10.249471,"twenty":-21.805571,"median":-18.455971,"eighty":-13.439317,"marketCap":415103594},{"date":"2023-09-29","current":-9.381898,"twenty":-21.588941,"median":-18.399822,"eighty":-13.144746,"marketCap":379966872},{"date":"2023-10-06","current":-9.926653,"twenty":-21.476513,"median":-18.254027,"eighty":-13.011583,"marketCap":402029465},{"date":"2023-10-13","current":-8.655558,"twenty":-21.471029,"median":-18.201253,"eighty":-12.658501,"marketCap":350550082},{"date":"2023-10-20","current":-8.221771,"twenty":-21.462802,"median":-18.183661,"eighty":-12.299366,"marketCap":332981721},{"date":"2023-10-27","current":-8.12089,"twenty":-21.457318,"median":-18.137991,"eighty":-12.28726,"marketCap":328896056},{"date":"2023-11-03","current":-7.868689,"twenty":-21.320668,"median":-17.990156,"eighty":-12.105675,"marketCap":318681893},{"date":"2023-11-10","current":-5.375877,"twenty":-21.183103,"median":-17.914995,"eighty":-11.823209,"marketCap":304177873},{"date":"2023-11-17","current":-4.874613,"twenty":-21.169392,"median":-17.861152,"eighty":-10.774051,"marketCap":275815341},{"date":"2023-11-24","current":-4.554966,"twenty":-21.169392,"median":-17.720421,"eighty":-10.138503,"marketCap":257729089},{"date":"2023-12-01","current":-4.838289,"twenty":-21.103581,"median":-17.57969,"eighty":-9.743051,"marketCap":273760085},{"date":"2023-12-08","current":-5.012642,"twenty":-21.06519,"median":-17.497596,"eighty":-9.458568,"marketCap":283625314},{"date":"2023-12-15","current":-5.993376,"twenty":-20.807428,"median":-17.409639,"eighty":-9.291106,"marketCap":339117223},{"date":"2023-12-22","current":-5.42673,"twenty":-20.459176,"median":-17.321682,"eighty":-8.792756,"marketCap":307055231},{"date":"2023-12-29","current":-6.225847,"twenty":-20.376911,"median":-17.198542,"eighty":-8.403356,"marketCap":352270861},{"date":"2024-01-05","current":-6.269435,"twenty":-20.360458,"median":-17.051947,"eighty":-8.171331,"marketCap":354737168},{"date":"2024-01-12","current":-6.552758,"twenty":-20.360458,"median":-16.876033,"eighty":-7.818248,"marketCap":370768164},{"date":"2024-01-19","current":-6.007906,"twenty":-20.163024,"median":-16.565251,"eighty":-6.745999,"marketCap":339939325},{"date":"2024-01-26","current":-7.729639,"twenty":-20.091727,"median":-16.395201,"eighty":-6.689335,"marketCap":437358455},{"date":"2024-02-02","current":-9.226167,"twenty":-20.060621,"median":-16.002326,"eighty":-6.745999,"marketCap":522034998},{"date":"2024-02-09","current":-10.192372,"twenty":-19.90434,"median":-13.48774,"eighty":-6.843346,"marketCap":576704805},{"date":"2024-02-16","current":-13.090301,"twenty":-19.80106,"median":-13.291023,"eighty":-7.190598,"marketCap":740675419},{"date":"2024-02-23","current":-13.68452,"twenty":-19.784607,"median":-13.356595,"eighty":-7.398369,"marketCap":774297534},{"date":"2024-03-01","current":-13.439842,"twenty":-19.727022,"median":-13.369934,"eighty":-7.593212,"marketCap":760453134},{"date":"2024-03-08","current":-12.216449,"twenty":-19.581688,"median":-13.356595,"eighty":-7.704554,"marketCap":691231132},{"date":"2024-03-15","current":-11.010534,"twenty":-19.485713,"median":-13.235538,"eighty":-7.770699,"marketCap":622998016},{"date":"2024-03-22","current":-9.036021,"twenty":-19.447295,"median":-13.106761,"eighty":-7.810178,"marketCap":649671871},{"date":"2024-03-28","current":-8.822029,"twenty":-19.362286,"median":-13.087259,"eighty":-7.838424,"marketCap":634286212},{"date":"2024-04-05","current":-8.704678,"twenty":-19.199155,"median":-13.043865,"eighty":-7.874093,"marketCap":625848914},{"date":"2024-04-12","current":-9.049827,"twenty":-19.019547,"median":-12.93794,"eighty":-7.899633,"marketCap":650664494},{"date":"2024-04-19","current":-7.42072,"twenty":-18.87571,"median":-12.8631,"eighty":-7.899633,"marketCap":533534959},{"date":"2024-04-26","current":-7.620907,"twenty":-18.835325,"median":-12.698294,"eighty":-7.82767,"marketCap":547927995},{"date":"2024-05-03","current":-9.036021,"twenty":-18.775904,"median":-12.579814,"eighty":-7.852557,"marketCap":649671871},{"date":"2024-05-10","current":-7.800135,"twenty":-18.750105,"median":-12.324461,"eighty":-7.852557,"marketCap":708236638},{"date":"2024-05-17","current":-7.190448,"twenty":-18.728996,"median":-12.28726,"eighty":-7.795318,"marketCap":652878301},{"date":"2024-05-24","current":-6.68739,"twenty":-18.728949,"median":-12.230329,"eighty":-7.639315,"marketCap":607201644},{"date":"2024-05-31","current":-6.791282,"twenty":-18.724211,"median":-12.17115,"eighty":-7.398356,"marketCap":616634866},{"date":"2024-06-07","current":-7.354489,"twenty":-18.70554,"median":-12.105675,"eighty":-7.206751,"marketCap":667772863},{"date":"2024-06-14","current":-6.938919,"twenty":-18.70554,"median":-12.055235,"eighty":-7.152172,"marketCap":630039972},{"date":"2024-06-21","current":-6.403053,"twenty":-18.680337,"median":-11.823209,"eighty":-7.108428,"marketCap":581384403},{"date":"2024-06-28","current":-6.288225,"twenty":-18.66581,"median":-11.779523,"eighty":-7.077807,"marketCap":570958210},{"date":"2024-07-05","current":-6.643646,"twenty":-18.632904,"median":-11.587276,"eighty":-6.982663,"marketCap":603229761},{"date":"2024-07-12","current":-7.420105,"twenty":-18.591772,"median":-11.06276,"eighty":-6.938919,"marketCap":673730687},{"date":"2024-07-15","current":-7.917695,"twenty":-18.591772,"median":-11.03634,"eighty":-6.947668,"marketCap":718910859},{"date":"2024-08-02","current":-6.588966,"twenty":-18.591772,"median":-11.027806,"eighty":-6.909392,"marketCap":598264907},{"date":"2024-08-09","current":-6.10778,"twenty":-18.590369,"median":-11.001795,"eighty":-6.863476,"marketCap":554574191},{"date":"2024-08-16","current":-4.055555,"twenty":-18.584183,"median":-10.737476,"eighty":-6.770215,"marketCap":485332348},{"date":"2024-08-23","current":-4.683003,"twenty":-18.568069,"median":-10.249471,"eighty":-6.677548,"marketCap":560419627},{"date":"2024-08-30","current":-5.223189,"twenty":-18.552105,"median":-10.150916,"eighty":-6.645833,"marketCap":625064304},{"date":"2024-09-06","current":-4.961407,"twenty":-18.537055,"median":-9.931698,"eighty":-6.596254,"marketCap":593736499},{"date":"2024-09-13","current":-4.815972,"twenty":-18.48037,"median":-9.781545,"eighty":-6.475316,"marketCap":576332163},{"date":"2024-09-20","current":-5.027891,"twenty":-18.464981,"median":-9.603836,"eighty":-6.37643,"marketCap":601692767},{"date":"2024-09-27","current":-4.982183,"twenty":-18.438212,"median":-9.472691,"eighty":-6.291732,"marketCap":596222833},{"date":"2024-10-04","current":-5.364469,"twenty":-18.421759,"median":-9.412162,"eighty":-6.214223,"marketCap":641971374},{"date":"2024-10-11","current":-5.576388,"twenty":-18.397637,"median":-9.311282,"eighty":-6.10778,"marketCap":667331978},{"date":"2024-10-18","current":-5.767531,"twenty":-18.36544,"median":-9.209355,"eighty":-5.996282,"marketCap":690206249},{"date":"2024-10-25","current":-5.651183,"twenty":-18.264582,"median":-9.139785,"eighty":-5.887312,"marketCap":676282780},{"date":"2024-10-31","current":-5.725979,"twenty":-18.236436,"median":-9.059079,"eighty":-5.811759,"marketCap":685233581},{"date":"2024-11-08","current":-5.883879,"twenty":-18.224708,"median":-9.036021,"eighty":-5.796618,"marketCap":704129718},{"date":"2024-11-15","current":-3.952188,"twenty":-18.201253,"median":-8.994603,"eighty":-5.767531,"marketCap":605684701},{"date":"2024-11-22","current":-3.854764,"twenty":-18.189525,"median":-8.953186,"eighty":-5.710053,"marketCap":590754101},{"date":"2024-11-29","current":-4.147037,"twenty":-18.189525,"median":-8.91986,"eighty":-5.679439,"marketCap":635545903},{"date":"2024-12-06","current":-3.968426,"twenty":-18.180143,"median":-8.904865,"eighty":-5.650352,"marketCap":608173135},{"date":"2024-12-13","current":-3.952188,"twenty":-18.114108,"median":-8.863447,"eighty":-5.605476,"marketCap":605684701},{"date":"2024-12-20","current":-3.841774,"twenty":-18.039908,"median":-8.833874,"eighty":-5.416559,"marketCap":588763354},{"date":"2024-12-27","current":-4.179512,"twenty":-18.004229,"median":-8.822029,"eighty":-5.28349,"marketCap":640522770},{"date":"2025-01-03","current":-3.978168,"twenty":-17.971392,"median":-8.704678,"eighty":-5.202978,"marketCap":609666195},{"date":"2025-01-10","current":-3.637182,"twenty":-17.941328,"median":-8.655558,"eighty":-5.112283,"marketCap":557409092},{"date":"2025-01-17","current":-3.08511,"twenty":-17.926192,"median":-8.487234,"eighty":-5.032877,"marketCap":472802355},{"date":"2025-01-24","current":-3.331919,"twenty":-17.896335,"median":-8.4084,"eighty":-5.007115,"marketCap":510626543},{"date":"2025-01-31","current":-3.335166,"twenty":-17.884608,"median":-8.283595,"eighty":-4.965562,"marketCap":511124230},{"date":"2025-02-07","current":-3.263722,"twenty":-17.861152,"median":-8.182593,"eighty":-4.939995,"marketCap":500175123},{"date":"2025-02-14","current":-2.858802,"twenty":-17.732149,"median":-8.12089,"eighty":-4.915699,"marketCap":508323497},{"date":"2025-02-21","current":-2.671017,"twenty":-17.722767,"median":-7.925786,"eighty":-4.894448,"marketCap":474933620},{"date":"2025-02-28","current":-2.791536,"twenty":-17.6497,"median":-7.886161,"eighty":-4.860849,"marketCap":496362944},{"date":"2025-03-07","current":-2.954095,"twenty":-17.590156,"median":-7.841803,"eighty":-4.835603,"marketCap":525267613},{"date":"2025-03-14","current":-3.783708,"twenty":-17.57969,"median":-7.799104,"eighty":-4.804337,"marketCap":672781099},{"date":"2025-03-21","current":-4.688995,"twenty":-17.560925,"median":-7.729639,"eighty":-4.688342,"marketCap":833750207},{"date":"2025-03-28","current":-4.20412,"twenty":-17.509324,"median":-7.643917,"eighty":-4.682096,"marketCap":747534555},{"date":"2025-04-04","current":-3.792116,"twenty":-17.497596,"median":-7.42072,"eighty":-4.627257,"marketCap":674276168},{"date":"2025-04-11","current":-4.438545,"twenty":-17.431922,"median":-7.387297,"eighty":-4.550381,"marketCap":789217694},{"date":"2025-04-17","current":-4.915534,"twenty":-17.408466,"median":-7.365425,"eighty":-4.554966,"marketCap":874031080},{"date":"2025-04-25","current":-5.140915,"twenty":-17.389702,"median":-7.190448,"eighty":-4.594195,"marketCap":914106052},{"date":"2025-04-29","current":-4.947538,"twenty":-17.38032,"median":-7.18498,"eighty":-4.620348,"marketCap":879721651}],"updateTime":1746034255838}}}